Meningococcal Immunization Against Gonococcal Infection (MAGI) Trial/ RV564

Awarded Limited / Sole Source Justification Posted

Solicitation number
HU000125CE001
Agency
Set-aside
No set-aside

Opportunity facts

Contract number
HU000125CE001 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

The DOD Uniformed Services University of the Health Sciences published a sole source justification notice for the Meningococcal Immunization Against Gonococcal Infection (MAGI) Trial/RV564, awarding contract HU000125CE001 to the Henry M. Jackson Foundation (HJF) on September 17, 2025. The contract covers a phase II randomized, placebo-controlled study to assess the efficacy of the meningococcal Group B vaccine rMenB+OMV NZ (Bexsero, GSK) in preventing gonococcal infection as part of the Infectious Disease Clinical Research Program's mission to reduce infectious disease impact in military populations. The sole source justification is based on statutory authorization under 10 U.S.C. 178, which permits USU to contract with HJF for cooperative medical research, with HJF being the only source capable of continuing ongoing protocols due to their pre-existing study sites, populations, enrolled subjects, and research data. The contract has an estimated total value of approximately $1,233,000 using a Cost-plus Fixed Fee mechanism, with a performance period from September 30, 2025, through September 29, 2027. The agency determined that switching contractors would result in unacceptable delays, making HJF uniquely qualified to execute this critical military health research initiative.

Notice text

Awarded contract HU000125CE001 to unknown vendor for unknown amount on 2025-09-17.

Files

File Type Posted
USUHS_JA_MAGI_Final_Redacted.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors